StocksRankings — AI Stock Picks & Rankings

AI Stock Picks — September 11, 2026

The 5 AI-selected stock picks for September 11, 2026 from StocksRankings — with full investment thesis, bull case, bear case, and key catalyst for each.

5 AI Stock Picks for September 11, 2026

  1. AMD — Advanced Micro Devices [Top Performer]
    Advanced Micro Devices is gaining market share in data center CPUs and GPUs, driven by hyperscaler demand and AI workloads. The company’s Genoa and MI300 product lines are ramping, with 195% EPS growth and $1B in buybacks confirming execution strength. The 1-year return of +231.55% reflects both momentum and a durable moat, and the PEG ratio of 0.66 signals further upside as earnings growth outpaces valuation.
    Key risk: A delay or underperformance in the MI300 ramp could slow revenue growth and erode share gains in high-performance compute.
  2. SNDK — Sandisk [Lowest PEG]
    Sandisk is expanding NAND flash and SSD shipments, benefiting from persistent demand in cloud storage and device refresh cycles. The company’s proprietary 3D NAND technology underpins a 247.5% EPS growth estimate, and a PEG ratio of 0.09 indicates the market is discounting its forward growth. The 1-year return of +1837.54% is extreme, but the moat in NAND process leadership and a forward P/E of 6.5x keep risk/reward attractive.
    Key risk: A sharp decline in NAND pricing or loss of a major OEM customer could compress margins and stall earnings growth.
  3. LLY — Eli Lilly and Company [Winner on a Dip]
    Eli Lilly is driving revenue growth through its GLP-1 franchise, including Mounjaro and Zepbound, which are expanding in diabetes and obesity indications. The company maintains a strong balance sheet with a $1.05T market cap, 1.6 current ratio, and 366% 5-year return, supporting continued pipeline investment. The RSI of 2.5 is extremely oversold, and the stock is 14% below its 52-week high, which presents a favorable entry if the recent selloff is sentiment-driven rather than fundamental.
    Key risk: A negative regulatory decision or safety signal on GLP-1 therapies could materially impact revenue growth and valuation.

See today's picks · full picks history · AI pick track record